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DJ-1PARK7, a cancer- and Parkinson’s disease (PD)-associated
protein, protects cells from toxic stresses. However, the functional
basis of this protection has remained elusive. We found that loss
of DJ-1 leads to deficits in NQO1 [NAD(P)H quinone oxidoreductase
1], a detoxification enzyme. This deficit is attributed to a loss of
Nrf2 (nuclear factor erythroid 2-related factor), a master regulator
of antioxidant transcriptional responses. DJ-1 stabilizes Nrf2 by
preventing association with its inhibitor protein, Keap1, and Nrf2’s
subsequent ubiquitination. Without intact DJ-1, Nrf2 protein is
unstable, and transcriptional responses are thereby decreased
both basally and after induction. This effect of DJ-1 on Nrf2 is
present in both transformed lines and primary cells across human
and mouse species. DJ-1’s effect on Nrf2 and subsequent effects on
antioxidant responses may explain how DJ-1 affects the etiology of
both cancer and PD, which are seemingly disparate disorders.
Furthermore, this DJ-1Nrf2 functional axis presents a therapeutic
target in cancer treatment and justifies DJ-1 as a tumor biomarker.
oxidative stress  PARK7  NQO1  Keap1  neurodegeneration
Oxidative stress has been implicated as a major contributingfactor in a wide variety of ailments. Cancer, cardiovascular
disease, neurodegenerative disorders, and aging all are associ-
ated with increased oxidative stress in tissues. Such stress results
from the accumulation of oxidative species due to their meta-
bolic generation and environmental exposures. These oxidative
species are detoxified by a gambit of antioxidant enzymes and
molecules. The balance between oxidative species generation
and removal determines the oxidative stress on a given tissue.
Not surprisingly, therefore, cellular responses to oxidative stress
are major determinants of disease susceptibility, particularly in
tissues that are sensitive to oxidative stress, such as in the central
nervous system. Genetic defects in oxidative responses lead to
neurodegenerative diseases. Examples include mutations in
SOD1 (superoxide dismutase 1) that lead to ALS (1) and loss of
DJ-1, which leads to early onset Parkinson’s disease (PD) with
high penetrance (2).
DJ-1 was initially described as a putative oncogene that is able
to transform cells weakly on its own and more strongly in
combination with Ras (3). DJ-1 is expressed at high levels in
primary lung and prostate cancer biopsies (4, 5), and its expres-
sion correlates negatively with clinical outcomes in nonsmall cell
lung carcinoma patients (6). The DJ-1 protein affects cell
survival, in part, by modulating cellular signaling cascades such
as PTENphosphatidylinositol 3-kinaseAkt (6) and altering
p53 activity (7). Additionally, we and others have previously
shown that DJ-1 expression in cancer cell lines conveys protec-
tion against stresses, including chemotherapy, oxidative stress,
endoplasmic reticulum stress, and proteosome inhibition (4, 8,
9). The mechanism by which DJ-1 imparts this protection
remains unknown. We report here that DJ-1 is required for the
activity of Nrf2 (nuclear factor erythroid 2-related factor), a
master regulator of response to oxidative stress.
Nrf2 is a member of the cap ’n’ collar family of basic leucine
zipper transcription factors that regulate the expression of many
antioxidant pathway genes (reviewed in ref. 10). Nrf2 is main-
tained at basal levels in cells by binding to its inhibitor protein,
Keap1 (11, 12). Keap1 is a BTB (Broad complex, Tramtrack,
Bric-a-Brac) domain-containing protein that targets Nrf2 for
ubiquitination by Cul3Roc-1, leading to its constitutive degra-
dation (13–16). Upon exposure to oxidative stress, xenobiotics,
or electrophilic compounds, Nrf2 protein is stabilized and
translocates to the nucleus (17). There, it forms heterodimers
with other transcription regulators, such as small Maf proteins,
and induces the expression of antioxidant genes (18, 19). Nrf2
drives the expression of detoxification enzymes, such as NQO1
[NAD(P)H quinone oxidoreductase 1] and Hmox-1, and en-
zymes that generate antioxidant molecules, such as glutathione
(20, 21). Nrf2 function and the expression of its regulated genes,
including NQO1, have been implicated in the risk andor
prevention of both cancer and PD (22–27).
In this study, we find that DJ-1 is required for the expression
of several genes, including the prototypic Nrf2-regulated anti-
oxidant enzyme NQO1. We report here that DJ-1 is indispens-
able for Nrf2 stabilization by affecting Nrf2 association with
Keap1, an inhibitor protein that promotes the ubiquitination and
degradation of Nrf2. These findings implicate DJ-1’s effects on
Nrf2 in the development of Parkinson’s disease and cancer and
present potential therapeutic targets.
Results
siRNA-Mediated Knockdown of DJ-1 and Affymetrix GeneChip Anal-
ysis. To explore DJ-1’s function, we examined its effect on global
gene expression. DJ-1 expression was reduced by siRNA in H157
non-small-cell lung carcinoma cells (Fig. 1). The characterization
of the antibody used to verify DJ-1 expression is shown in Fig.
6, which is published as supporting information on the PNAS
web site. The first DJ-1 siRNA (referred to as siDJ-1#1) caused
a modest decrease in DJ-1, whereas siDJ-1#2 caused a profound
decrease. RNA samples from cells with siDJ-1#1, two control
scrambled oligomers (siCTL), and one mock-transfected sample
were subjected to GeneChip profiling (Affymetrix, Santa Clara,
CA). To ensure that changes warranted further study, we
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stringently filtered expression to exclude differences 3-fold and
any genes having spots with a raw signal intensity of 500 units
in the samples where a gene was determined to be present. This
stringent filtering produced a list of 3 genes that were increased
and 14 genes that were decreased in cells with siDJ-1 (Fig. 2). As
expected, siDJ-1 reduced DJ-1 expression.
Among the genes whose expression decreased in the absence of
DJ-1, one of particular interest was NQO1. NQO1 is a well
described detoxification enzyme (28) that has been implicated in
the risk and prevention of cancer and neurodegenerative diseases
(29–32). NQO1 is regulated to a large degree by gene transcription
by means of an antioxidant response element (ARE) in its pro-
moter (33), which is a prototypic target of the antioxidant tran-
scription factor Nrf2 (20). With this fact in mind, we used the
tfsearch algorithm (as in ref. 34) to search for putative AREs within
1,000 bp upstream of the transcriptional start site of the genes
identified in Fig. 2. Seven of 17 genes that were changed by 3-fold
by siDJ-1 contained an ARE-like sequence (TMAnnRTGAY-
nnnGCRwwww) in their promoters (Fig. 2, rightmost column). We
then reanalyzed our microarray data with respect to Nrf2 and found
that several Nrf2-regulated genes were altered in the absence of
DJ-1 (Fig. 7, which is published as supporting information on the
PNAS web site). All array data have been deposited in the Gene
Expression Omnibus online repository.
DJ-1 Is Required for Nrf2-Mediated Transcription. To verify the
microarray data, we used NQO1 as a prototypic target gene of
DJ-1. Real-time PCR analysis shows that siDJ-1#2 reduced DJ-1
and NQO1 by 80%. However, Nrf2 mRNA expression was not
changed (Fig. 3A), indicating that NQO1 expression differences
are not due to a reduction of Nrf2 mRNA. To determine whether
DJ-1 affects NQO1 gene transcription by means of Nrf2 func-
tion, we used a reporter construct, pGL2-ARE, which contains
the firefly luciferase gene under the control of an ARE from the
human NQO1 promoter (Fig. 3B). This construct was tested in
the absence or presence of DJ-1. The liver cell line Huh7 was
used because Nrf2 activity can be induced in these cells by the
nontoxic food preservative tert-butylhydroquinone (tBHQ) (35).
Cells were treated with either 50 M tBHQ or DMSO vehicle
control, and luciferase activity was measured (Fig. 3B). Flag-
Nrf2 was transfected into cells as a positive control. Overex-
pressed Nrf2 robustly activated ARE-regulated luciferase (Fig.
3B, lanes 1 vs. lane 2). Cells with siCTL produced a basal level
of luciferase, whereas tBHQ induced luciferase expression as
expected (36) (Fig. 3B, lanes 3 and 4). In the presence of
siDJ-1#1 or siDJ-1#2, luciferase activity was reduced (Fig. 3B,
lanes 5 and 7), and it was no longer stimulated by tBHQ
treatment (lanes 6 and 8). This effect is specific for the ARE
element, as evidenced by the fact that siDJ-1 did not affect other


















































Fig. 1. siRNA-mediated knockdown of DJ-1 and GeneChip analysis. (A)
End-point RT-PCR of H157 cells transfected with control siRNA (siCTL) or two
different siRNA targeting DJ-1 (siDJ-1#1 and siDJ-1#2). The DJ-1 RT-PCR gel is
presented as a negative image so bands can be more easily visualized. NTC is
a nontemplate control. (B) Western blot analysis of siRNA-transfected H157
cells demonstrating DJ-1 knockdown at the protein level. (C) Quantitative
real-time PCR of DJ-1 mRNA after siRNA transfection. Relative mRNA quanti-
tation is normalized to 18S rRNA expression. siDJ-1#2 reduced DJ-1 expression
to a greater degree than siDJ-1#1, whereas transfection with either a scram-
bled nonspecific oligomer siRNA or transfection reagent alone (siMOCK) did







































 TOMM20 TRANSLOCASE OF OUTER MITOCHONDRIAL MEMBRANE 20 -5.02 
 RRN3 RNA POLYMERASE I TRANSCRIPTION FACTOR -4.81 
 P24A/TMED2   TRANSMEMBRANE EMP24 TRANSPORT DOMAIN-CONTAINING PROT. -4.34 
 LAMP1 LYSOSOME-ASSOCIATED MEMBRANE PROTEIN 1 -4.33
 ABCC3 ATP-BINDING CASSETTE, SUBFAMILY C, MEMBER 3 -3.88 
 CLNS1A CHLORIDE CHANNEL, NUCLEOTIDE SENSITIVE, 1A -3.79 
 DJ-1 ONCOGENE DJ-1/PARK7 -3.69 
 PSIP1 PC4- AND SFRS1-INTERACTING PROTEIN 1 -3.57 
 OB-RG/LEPR LEPTIN-RELATED GENE/LEPTIN RECEPTOR -3.49 
 RAB14 RAS-ASSOCIATED PROTEIN -3.38 
 PIGB PHOSPHATIDYLINOSITOL GLYCAN, CLASS B -3.35 
 NQO1 NAD(P)H DEHYDROGENASE, QUINONE 1 -3.32 
 HRASLS3 HRAS-LIKE SUPPRESSOR 3 -3.31 
 NOG1 NOGGIN HOMOLOG -3.02 
 GREM1 GREMLIN 1 HOMOLOG, CYSTEINE KNOT SUPERFAMILY +4.00
 CALR CALRETICULIN +3.27 







Upstream ARE-like sequenceFold Change
Fig. 2. Summary of Affymetrix GeneChip analysis. Genes shown represent changes of 3-fold between siCTL- and siDJ-1-transfected samples; fluorescence in
the present (P) state is 500 in all samples. Green indicates decreased expression in normalized fluorescence; red indicates higher expression. Putative
Nrf2-binding sequences within 1,000 bp upstream of the transcription start site are included to the right where present and were identified by using tfsearch
and a score of 85.0.




















DJ-1 Is Required for Nrf2 Protein Stability. Given that DJ-1 was
required for both basal and induced ARE-driven transcription, we
explored some possible mechanisms. DJ-1 was not associated with
the NQO1 promoter as assessed by chromatin immunoprecipitation
assay, suggesting that DJ-1 is not likely tethered on the NQO1
promoter with Nrf2 (Fig. 8, which is published as supporting
information on the PNAS web site). Furthermore, RNA expression
of Nrf2 (see Fig. 2A) or its inhibitor, Keap1, was not changed by
siDJ-1 (Fig. 9, which is published as supporting information on the
PNAS web site). However, Western blot analysis revealed that Nrf2
protein expression was drastically reduced in the absence of DJ-1,
with siDJ-1#1 causing a more modest decrease and siDJ-1#2
causing a dramatic decrease (Fig. 4A), consistent with the level of
DJ-1 reduction achieved with these two siRNA (see Fig. 1A).
To determine whether DJ-1 reduced Nrf2 stability, DJ-1 was
decreased by siDJ-1 in Huh7 cells, and the cells were treated with
the translation inhibitor cyclohexamide to prevent new protein
synthesis. Cells were lysed at various time points, and the
degradation kinetics of Nrf2 and actin (as a control) was
analyzed by Western blot. Nrf2 protein was decreased by siDJ-1
compared with siCTL or transfection reagents alone, and, by 90
min, Nrf2 disappeared in cells with siDJ-1 (Fig. 4B), indicating



















































































































































Fig. 3. DJ-1 is required for Nrf2-mediated transcription. (A) Real-time quan-
titative PCR analysis of mRNA expression verifies that siDJ-1#2 reduced DJ-1
mRNA expression, as well as NQO1 mRNA expression. However, the mRNA of
Nrf2, a master regulator of NQO1 expression, is unaffected by the loss of DJ-1.
All experiments were performed in triplicate, and error bars indicate SEM. (B)
ARE-regulated luciferase reporter gene activity in Huh7 cells is reduced after
siDJ-1 transfection. The firefly luciferase reporter construct is under the con-
trol of the NQO1 ARE (43), which is responsive to Nrf2. Cells were treated with
50 M tBHQ or a DMSO vehicle control. Lysates were assayed for luciferase
activity and normalized to crude protein present in the extract. Flag-Nrf2 was
transfected as a positive control. Samples with lowered DJ-1 expression con-
tained lower levels of the ARE-regulated luciferase activity and failed to
increase luciferase activity after treatment with tBHQ. All experiments were
performed in triplicate, and error bars indicate SEM. (C) Luciferase activity
expressed from a construct under the control of the constitutively active viral
SV40 promoter was not affected by siDJ-1. (D) Luciferase activity expressed
from two mammalian promoters was not affected by siDJ-1. Huh7 cells with
siDJ-1 were transfected with luciferase reporter constructs under control of
the NQO1 ARE, glucocorticoid response element (GRE), or cAMP response
element (CRE). Cultures were treated with the appropriate vehicle control, 50
M tBHQ, 100 M dexamethasone (DEX), or 10 M forskolin (FOR) as indi-
cated. Activation is presented as the percentage induction of control oligomer
(siCTL)-transfected cells. All experiments were replicated at least three times.
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Fig. 4. DJ-1 is required for Nrf2 protein stability. (A) Western blot analysis of
Nrf-2, DJ-1, and control proteins in Huh7 cell lysates after siRNA knockdown
of DJ-1. (B) Time course of protein expression after cyclohexamide (CHX)
treatment. Western blot analysis confirms the presence of Nrf2 at times after
CHX treatment in control samples. Actin is used as an unaffected control. (C)
In cellulo assay of Nrf2 ubiquitinylation. Nrf2 and covalently bound ubiquitin
were immunoprecipitated from Huh7 extracts and analyzed by SDSPAGE and
Western blot analysis. (D) Nrf2Keap1 coimmunoprecipitation in the presence
of DJ-1. V5 epitope-tagged Keap1 was expressed in Huh7 cells with and
without overexpressed Flag-DJ-1. Immunoprecipitation using anti-V5 anti-
body coimmunoprecipitated endogenous Nrf2 protein, and, conversely, im-
munoprecipitation of endogenous Nrf2 coisolated V5-Keap1. ‘‘H.C.’’ denotes
a cross-reacting band of IgG heavy chain that was present from the immuno-
precipitating antibody. Data are representative of at least three independent
experiments.



























Nrf2 protein stability is an important regulatory event that is
tightly controlled by its association with a cytosolic inhibitor
protein, Keap1 (11, 12). Under unstimulated conditions, Nrf2
associates with Keap1, which targets Nrf2 for ubiquitination by
a Cullin-3-dependent mechanism (13–16), leading to proteo-
some-dependent degradation (37). Given our data implicating
DJ-1 in Nrf2 stability, we tested DJ-1’s effect on Nrf2 ubiquiti-
nation (Fig. 4C). Huh7 cells expressing HA-tagged ubiquitin and
Nrf2 were transfected with DJ-1 or pcDNA. Nrf2 was immu-
noprecipitated from denatured lysates, isolating only molecules
covalently linked to Nrf2. Ubiquitin-Nrf2 conjugates were visu-
alized by immunoblotting for the ubiquitin epitope HA. Nrf2 was
ubiquitinated to a much lesser degree when DJ-1 was overex-
pressed (Fig. 4C, upper blot, lanes 1 and 2), correlating with an
increase of Nrf-2 protein in the presence of DJ-1 (lower blot).
The addition of the proteosome inhibitor MG132 prevented
degradation of ubiquitinated Nrf2 (Fig. 4C, lanes 5 and 6).
Given that the association of Keap1 with Nrf2 is known to
trigger Nrf2 ubiquitinationdegradation (38) and that DJ-1
reduces Nrf2 ubiquitination, we determined whether DJ-1 af-
fects the association of Nrf2 and Keap1. Huh7 cells were
transfected with V5-tagged Keap1 (the tagged epitope is re-
quired because of the lack of a sufficient and commercially
available Keap1 antibody). The anti-V5 antibody recognized
V5-Keap1 and coimmunoprecipitated Nrf2 (Fig. 4D, lane 1); the
inclusion of Flag-DJ-1 eliminated this coimmunoprecipitation
(Fig. 4D, lane 2). Reverse immunoprecipitation shows that
antibody to endogenous Nrf2 coprecipitated V5-Keap1 (Fig. 4D,
lane 4), which was also decreased by Flag-DJ-1 (lane 5). These
data suggest that DJ-1 stabilizes Nrf2 by preventing its associ-
ation with Keap1.
Although the above experiments demonstrate a strong func-
tional link between DJ-1 and Nrf2, we have so far been unable
to determine where DJ-1 physically exerts this effect. Coimmu-
noprecipitation experiments have failed to find DJ-1 in physical
association with Nrf2, Keap1, or Cullin-3 (Fig. 10, which is
published as supporting information on the PNAS web site).
Therefore, it remains to be determined whether DJ-1’s profound
effect on Nrf2 is the result of direct or indirect molecular
mechanisms.
DJ-1 Is Required for Nrf2 Function in Primary Mouse Embryonic
Fibroblasts (MEFs). To determine whether DJ-1 is required for
Nrf2 expression in primary untransformed cells, we isolated
day-13.5 MEFs from DJ-1/ mice (39) and induced Nrf2
protein expression by using tBHQ treatment. tBHQ induced
murine Nrf2 (mNrf2) protein expression in WT littermates (n 
4; two are shown in Fig. 5A), whereas DJ-1/ mice failed to
show induced mNrf2 expression (n  4; two are shown in Fig.
5A). Restoration of DJ-1 with a Flag-DJ-1 expression plasmid
also restored Nrf2 protein expression with tBHQ treatment (Fig.
5B), which indicates that the loss of Nrf2 protein in DJ-1/
fibroblasts is a specific consequence of the loss of DJ-1.
To examine the necessity of DJ-1 for Nrf2 function, we
resorted to the Nrf2-activated reporter plasmid pGL2-ARE.
DJ-1/ and DJ-1/ MEFs from four mice (two representatives
are shown in Fig. 5C) were separately transfected with pGL2-
ARE and then induced with 50 M tBHQ. WT DJ-1/ cells
showed increased luciferase expression upon tBHQ treatment,
whereas DJ-1/ cells did not (Fig. 5C Left). SV40 promoter
activity was independent of DJ-1 (Fig. 5C Right).
To use a more physiologic measurement, we tested the effect
of DJ-1 on the expression of Nrf2-regulated detoxification
enzymes: NQO1 and GCLM (glutathione cysteine ligase mod-
ifier subunit) (Fig. 5D). Based on the microarray analysis (Fig.
7), siDJ-1 reduced GCLM expression by 1.478-fold; hence, we
selected it in addition to NQO1 for further analysis. Induction of
MEF cultures with 25 M tBHQ led to a substantial increase of
mNQO1 in DJ-1/ MEFs, but this increase was drastically
reduced in DJ-1/ cells. This pattern is also found for murine
GCLM. However, at higher (100 M) dosage, even though
differences in mNrf2 protein expression persisted (Fig. 5A),
induction of detoxification enzymes was only slightly reduced in
DJ-1/ compared with DJ-1/ MEFs (Fig. 11, which is pub-
lished as supporting information on the PNAS web site), indi-
cating that a high concentration of tBHQ can activate a DJ-1-
independent pathway to cause NQO1 and GCLM expression.
Discussion
In summary, this work describes functional effects of the DJ-1
protein by means of Nrf2, a master regulator of antioxidant gene
responses. Cancer and PD lie at opposite ends of a spectrum
defined by dysfunctions in cell death. Our finding may explain
how DJ-1 plays an important role in both diseases. One of the
hallmarks of PD is the loss of substantia nigra dopaminergic
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Fig. 5. DJ-1 is required for Nrf2 function in MEFs. (A) Western blot analysis
of mNrf2 protein expression in primary MEFs derived from DJ-1 gene deletion
mice and WT littermates. Cultures were treated with tBHQ at 0, 50, and 100
M. (B) Western blot analysis of mNrf2 cultures transfected with either pcDNA
or Flag-DJ-1 and treated with 50 M tBHQ or vehicle control. (C) ARE-
luciferase activity in DJ-1/ and DJ-1/ MEF cultures. Luciferase is under
control of the ARE from the human NQO1 gene promoter (Left); SV40-
luciferase is under control of the constitutively active viral SV40 promoter
(Right). Luciferase activity is normalized to protein concentration in the
extract. (D) Real-time quantitative PCR of Nrf2-mediated target gene expres-
sion in primary MEFs. NQO1, NAD(P)H quinone oxidoreductase I; GCLM,
glutathione cysteine ligase modifier subunit. Data are presented as fold
induction after treatment with tBHQ compared with vehicle control. All
mRNA measurements are normalized to mouse G3PDH expression. All exper-
iments were performed in triplicate, and error bars indicate SEM. All data are
representative of at least three independent experiments.




















exhibit widespread neuronal loss in a PD disease model (39, 41),
but these neurons were more susceptible to death after toxic
insults (39). Likewise, human neuronal cell lines with DJ-1
knockdown are more sensitive to toxic compounds (8, 9). The
loss of antioxidant gene transcription could account for these
phenotypes that are only evident after environmental harm.
It is noteworthy that we initially identified DJ-1’s effect on
Nrf2 in lung tumor cells. Studies of Nrf2 knockout mice show
that Nrf2 plays a significant role in lung biology (reviewed in
ref. 10). In our studies, we found that the H157 lung tumor cells
did not consistently induce Nrf2 activity after tBHQ treat-
ment; instead, they had a very high basal level of activity that
was not inducible by treatment (data not shown). High basal
NQO1 expression allowed us to confidently quantify changes
in NQO1 expression and implicated the broader effect of DJ-1
on Nrf2. To study gene induction, we then used liver cell line
models, which are highly inducible. These models allowed us
to identify the effects of DJ-1 on Nrf2, which heretofore
remained unrecognized.
Enhanced expression of DJ-1 in cancer cells, leading to
increased detoxification enzymes, is likely to provide a survival
advantage. These enzymes may be exploited as treatment targets
in tumors. For example, NQO1, an obligate two-electron reduc-
tase, can reduce antitumor quinones, leading to their bioactiva-
tion. Mitomycin C (MMC) and the antitumor compound 2,5-
diaziridinyl-3- (hydroxymethyl)-6-methyl-1,4-benzoquinone are
activated by NQO1 activity, and NQO1 is shown to increase the
efficacy of MMC in vivo (42). It is possible that tumors with high
DJ-1 levels might be more susceptible to therapies that rely on
enzymes such as NQO1, underscoring the potential of DJ-1 as
a biomarker to define specific antitumor therapies.
Materials and Methods
Cell Cultures, Treatments, and Plasmid Constructs. Huh7 cells were
grown in DMEM (Sigma, St. Louis, MO) with 7% FCS. H157
cells were grown in RPMI medium 1640 (Gibco, Carlsbad, CA)
plus 10% FCS. All mammalian cell cultures were grown in the
presence of penicillin and streptomycin to minimize contami-
nation effects.
tBHQ (Fluka, St. Louis, MO) was dissolved in DMSO (final
concentration on cells was 0.0001%), and cells were treated for
18–24 h. Dexamethasone and forskolin (MP Biochemicals,
Irvine, CA) were dissolved in DMSO and ethanol, respectively.
Dexamethasone was used at a final concentration of 100 M, and
forskolin was used at 10 M. In experiments determining Nrf2
protein stability, cells were treated with cyclohexamide (Sigma)
in DMSO at a concentration of 75 gml for up to 2 h. The
peptide proteosome inhibitor MG132 (Calbiochem, San Diego,
CA) was used at 25 M for 4–6 h for ubiquitination studies.
Other investigators generously provided Flag-DJ-1 (5), Flag-
Nrf2 (16), and hNQO1-ARE-pGL2 (43) plasmids. SV40-
luciferase (pGL3-control), GRE-luciferase (pGRE-Luc, Clon-
tech, Mountain View, CA), and CRE-luciferase (pCRE-Luc;
Clontech) were all purchased from commercial sources. We
directionally cloned human Keap1 into the V5His-containing
pcDNA3.1D-Topo plasmid (Invitrogen, Carlsbad, CA) by am-
plifying the Keap1 ORF with the primers 5-CACCATGCAGC-
CAGATCCCAGGCCTAGC-3 and 5-ACAGGTACAGTTC-
TGCTGGTCAATCT-3 by using platinum-pfx polymerase (In-
vitrogen). Clone directionality and expression was verified by
sequencing and Western blot analysis. Human cell lines were
transfected with DNA by using FuGENE 6 (Roche, Basel,
Switzerland), and MEF cultures were transfected with Lipo-
fectamine 2000 (Invitrogen) per the manufacturer’s instructions.
siRNA Knockdown of DJ-1. Cell lines were transfected with siDJ-1-1
5-NNGACCCAGUACAGUGUAGCC-3, siDJ-1-2 5-NNUG-
GAGACGGUCAUCCCUGU-3, scrambled control oligomer
(Xeragon, Huntsville, AL), siCONTROL (siCTL) nontargeting
siRNA no. 1 (Dharmacon, Lafayette, CO), or transfection reagent
alone by using Oligofectamine (Invitrogen) for H157 cells and
Lipofectamine 2000 (Invitrogen) for Huh7 cells per the manufac-
turer’s protocols. Cells were transfected on consecutive days for 2–3
days in a row, and lysates were taken for RNA and protein analysis
96 h after the first transfection.
Generation of Anti-DJ-1 Antibody. DJ-1 was cloned into 6 histi-
dine-tagged Escherichia coli overexpression vector QE82L (Qia-
gen, Valencia, CA) by standard methodology. Expression of
DJ-1 was induced with 1 mM isopropyl--D-thiogalactopyrano-
side in the E. coli strain BL21 (DE3). Cells were lysed in PBS plus
EDTA-free protease inhibitor mixture (Roche), and DJ-1 was
purified to 95% homogeneity with Ni-nitrilotriacetic acid
(Qiagen) according to the manufacturer’s instructions. Recom-
binant DJ-1 was sent to Proteintech Group (Chicago, IL) for the
production of the anti-DJ-1 rabbit polyclonal serum.
Affymetrix GeneChip Analysis. Total RNA isolated from H157 cells
was DNase I-treated and column-purified (Promega, Madison,
WI). The quality of the RNA was determined by formamide-
agarose electrophoresis and comparison of expression of house-
keeping genes. Seven micrograms of total RNA was used to
synthesize cDNA. A custom cDNA kit from Life Technologies
(Carlsbad, CA) was used with a T7-(dT)24 primer for this
reaction. Biotinylated cRNA was then generated from the cDNA
reaction by using the BioArray High Yield RNA transcript kit
(Ento Life Sciences, Farmingdale, NY). The cRNA was frag-
mented in fragmentation buffer (5 fragmentation buffer: 200
mM Tris-acetate, pH 8.1500 mM KOAc150 mM MgOAc) at
94°C for 35 min before the chip hybridization. Fragmented
cRNA (15 g) was then added to the hybridization mixture (0.05
g/l fragmented cRNA50 pM control oligonucleotide B2,
BioB, BioC, BioD, and cre hybridization controls0.1 mg/ml
herring sperm DNA0.5 mg/ml acetylated BSA100 mM Mes1
M [Na]20 mM EDTA0.01% Tween 20). Ten micrograms of
cRNA was used for hybridization. Arrays were hybridized for
16 h at 45°C in the GeneChip Hybridization Oven 640. The
arrays were washed and stained with R-phycoerythrin strepta-
vidin in the GeneChip Fluidics Station 400. After this, the arrays
were scanned with a GeneArray scanner (Hewlett–Packard, Palo
Alto, CA). Affymetrix GeneChip Microarray Suite 5.0 software
was used for washing, scanning, and basic analysis. Sample
quality was assessed by examination of 3 to 5 intensity ratios of
certain genes.
These data were then further analyzed, filtered, and compared
by using GeneSpring software (Silicon Genetics, Redwood City,
CA). Genes defined as ‘‘changed’’ were filtered to include those
differing 3-fold between both siCTL chips and siDJ-1 chips,
with a raw fluorescence intensity of at least 500 in both of the
highly expressed (present) arrays. Both siDJ-1 arrays were
transfected with siDJ-1#1 and then verified by real-time PCR
using both siDJ-1#1 and siDJ-1#2.
Real-Time Quantitative PCR. Reactions were carried out in an ABI
7900HT PCR system (Applied Biosystems, Foster City, CA) using
a 15-l, 384-well format and master mixes from ABGene (Roch-
ester, NY). TaqMan PCR primerprobe sets were designed for
human DJ-1: primer 1, 5-CCATATGATGTGGTGGTTCTAC-
3; primer 2, 5-ACTTCCACAACCTATTTCATGAG-3; probe,
5-[6-FAM]ACCTGCACAGATGGCGGCTATCA[Tamra-Q]-3.
Primerprobe sets for human NQO1 were as follows: primer 1,
5-CCGTGGATCCCTTGCAGAGA-3; primer 2, 5-AGGAC-
CCTTCCGGAGTAAGA-3; probe, 5-[6-FAM]ACATGGAGC-
CACTGCCACCA[Tamra-Q]-3. SYBR green real-time PCR
primers were designed for human Nrf2: primer 1, 5-AGTG-
GATCTGCCAACTACTC-3; primer 2, 5-CATCTACAAA-



























CGGGAATGTCTG-3. We used previously published mouse
G3PDH primers that were designed to be used with SYBR green
quantitation (44). Predesigned TaqMan PCR primer and probe sets
were purchased from Applied Biosystems for mouse NQO1 and
GCLM.
Luciferase Reporter Gene Assays. Cells were grown and transfected
as described above in six-well plates (Falcon, San Jose, CA).
Cultures were lysed in reporter lysis buffer (Promega) by using
a single round of freeze–thaw at 80°C. Luciferase assays were
then performed as described in ref. 45.
Western Blot Analysis and Immunoprecipitation. For all Western blot
analyses, cells were lysed in RIPA buffer (10 mM NaPO4, pH
7.4300 mM NaCl0.1% SDS1% Nonidet P-401% deoxycholic
acid2 mM EDTA) with protease inhibitors (Roche), diluted with
SDS loading buffer, and boiled in the presence of the reducing
agent DTT. Proteins were then separated by molecular weight by
SDSPAGE through polyacrylamide gels ranging from 6% to 12%.
Proteins were electrophoretically transferred to nitrocellulose
membranes and blocked by using 5% nonfat dry milk in TBS with
0.1% Tween 20. Antibodies used for blotting were anti-Nrf2 H-300
(Santa Cruz Biotechnology, Santa Cruz, CA), rabbit polyclonal
anti-DJ-1, anti-actin-HRP (Santa Cruz Biotechnology), anti-
G3PDH, anti-HA-HRP (Roche), and anti-Flag (M2)-HRP
(Sigma).
Protein complexes were isolated from cell lysates by immu-
noprecipitation using antibodies specific for Nrf2 (H-300, Santa
Cruz Biotechnology) and anti-V5 (Invitrogen), followed by
incubation with protein AG agarose (Pierce Biotechnologies,
Rockford, IL). Protein AG antibody–protein complexes were
washed extensively and eluted by boiling in loading buffer with
reducing equivalents. Eluates and input lysate controls were then
Western blotted to assay for protein expression and isolation.
Ubiquitination assays were performed in Huh7 cells trans-
fected with epitope-tagged Nrf2 and ubiquitin grown in 100-mm2
plates. The cells were lysed in 200 l of SDS lysis buffer (50 mM
TrisHCl, pH 7.50.5 mM EDTA1% SDS1 mM DTT) and
boiled for 10 min. Cellular debris was pelleted, and SDS con-
centrations were diluted by the addition of 1,200 l of 0.5%
Nonidet P-40 lysis buffer with added protease inhibitors. Anti-
Flag (M2) agarose was then added and incubated for 14–16 h.
The agarose matrix was washed extensively with 0.5% Nonidet
P-40 lysis buffer, and the proteins were eluted by boiling in 2
loading buffer with DTT. The eluates were then analyzed by
Western blot analysis for the expression of the epitope tags.
DJ-1 Knockout Mice and Embryonic Fibroblast Culture. DJ-1 knock-
out mice and WT littermates (39), backcrossed six generations
onto the C57BL6 strain, were housed according to the guidelines
of the National Institutes of Health under an approved Institu-
tional Animal Care and Use Committee protocol at the Uni-
versity of North Carolina. Primary MEFs were isolated from
day-13.5 embryos and grown in DMEM supplemented with 10%
FCS. All MEF experiments were performed on cells within two
cell passages of isolation from the mice.
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